MedTrace Logo

Erlotinib and Sunitinib in NSCLC

NCT00581789 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2019-11-19

No results posted yet for this study

Summary

* To determine the safety and maximally tolerated dose of sunitinib plus erlotinib in patients with non-small cell lung cancer (NSCLC).
* To determine response to sunitinib plus erlotinib in patients with non-small cell lung cancer.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

erlotinib, sunitinib

erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Genentech, Inc.

    collaborator INDUSTRY

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Anne Traynor, MD · University of Wisconsin, Madison

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2010-02-28
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00581789 on ClinicalTrials.gov